Takeda, Santhera Extend Partnership On Idebenone To Duchenne Muscular Dystrophy
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda and the Swiss specialty pharma Santhera Pharmaceuticals are extending an existing collaboration on SNT-MC17 (idebenone) for the neuromuscular disease Friedreich's Ataxia to include a second indication for Duchenne muscular dystrophy, the firms announced Aug. 2
You may also be interested in...
Duchenne Muscular Dystrophy: Ripened Science, Another Deal
BioMarin, licensing preclinical utrophin booster from Summit, targets another niche.
Duchenne Muscular Dystrophy: Ripened Science, Another Deal
BioMarin, licensing preclinical utrophin booster from Summit, targets another niche.
AVI BioPharma Discontinues Hep C Candidate Due To Insufficient Potency
Company to refocus development of its Neugene antisense compounds on cardiovascular and genetic diseases.